Lupin Ltd., of Mumbai, and Boehringer Ingelheim GmbH, of Ingelheim, Germany, said they inked an alliance to co-market Boehringer's linagliptin, a DPP-4 inhibitor, in India. Under the terms, Lupin will market and sell the drug under the brand Ondero (monotherapy) and Ondero Met (fixed-dose combination with metformin), using its 400-strong diabetes specialty field force.